SARCOMA

Vicki Keedy, MD, Assistant Professor of Medicine, Clinical Director, Sarcoma Program, Vanderbilt-Ingram Cancer Center, discusses pazopanib for the treatment of soft tissue sarcoma.

Vicki Keedy, MD, Assistant Professor of Medicine, Clinical Director, Sarcoma Program, Vanderbilt-Ingram Cancer Center, discusses the cytotoxic chemotherapy TH-302.

Belinostat (PXD101), in combination with doxorubicin, could provide benefit for patients with soft tissue sarcomas, according to final results from the first stage of the phase II portion of the phase I/II CLN-14 clinical trial.

Aldoxorubicin demonstrated response rates that culminated in a higher incidence of stable disease versus doxorubicin as a first-line treatment for advanced soft tissue sarcomas, according to results from an ongoing phase IIb study.

Vicki Keedy, MD, Assistant Professor of Medicine, Clinical Director, Sarcoma Program, Vanderbilt-Ingram Cancer Center, discusses novel agents that are currently under investigation for the treatment of gastrointestinal stromal tumors